| pubmed-article:9784102 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9784102 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:9784102 | lifeskim:mentions | umls-concept:C1519554 | lld:lifeskim |
| pubmed-article:9784102 | lifeskim:mentions | umls-concept:C1707689 | lld:lifeskim |
| pubmed-article:9784102 | lifeskim:mentions | umls-concept:C1705938 | lld:lifeskim |
| pubmed-article:9784102 | lifeskim:mentions | umls-concept:C1527178 | lld:lifeskim |
| pubmed-article:9784102 | pubmed:issue | 22 | lld:pubmed |
| pubmed-article:9784102 | pubmed:dateCreated | 1998-11-23 | lld:pubmed |
| pubmed-article:9784102 | pubmed:abstractText | A new class of pyridobenzophenoxazine compounds has been developed as topoisomerase II inhibitors for anticancer chemotherapy. These compounds were designed based on a proposed model of a quinobenzoxazine self-assembly complex on DNA. They showed excellent inhibitory effects on several tumor cell lines with nanomolar IC50 values. Their cytotoxic potency correlates with their ability to unwind DNA and inhibit topoisomerase II. | lld:pubmed |
| pubmed-article:9784102 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9784102 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9784102 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9784102 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9784102 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9784102 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9784102 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9784102 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9784102 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9784102 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9784102 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:9784102 | pubmed:issn | 0022-2623 | lld:pubmed |
| pubmed-article:9784102 | pubmed:author | pubmed-author:HurleyL HLH | lld:pubmed |
| pubmed-article:9784102 | pubmed:author | pubmed-author:MangoldGG | lld:pubmed |
| pubmed-article:9784102 | pubmed:author | pubmed-author:KwokYY | lld:pubmed |
| pubmed-article:9784102 | pubmed:author | pubmed-author:ZeniSS | lld:pubmed |
| pubmed-article:9784102 | pubmed:author | pubmed-author:KerwinS MSM | lld:pubmed |
| pubmed-article:9784102 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9784102 | pubmed:day | 22 | lld:pubmed |
| pubmed-article:9784102 | pubmed:volume | 41 | lld:pubmed |
| pubmed-article:9784102 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9784102 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9784102 | pubmed:pagination | 4273-8 | lld:pubmed |
| pubmed-article:9784102 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:9784102 | pubmed:meshHeading | pubmed-meshheading:9784102-... | lld:pubmed |
| pubmed-article:9784102 | pubmed:meshHeading | pubmed-meshheading:9784102-... | lld:pubmed |
| pubmed-article:9784102 | pubmed:meshHeading | pubmed-meshheading:9784102-... | lld:pubmed |
| pubmed-article:9784102 | pubmed:meshHeading | pubmed-meshheading:9784102-... | lld:pubmed |
| pubmed-article:9784102 | pubmed:meshHeading | pubmed-meshheading:9784102-... | lld:pubmed |
| pubmed-article:9784102 | pubmed:meshHeading | pubmed-meshheading:9784102-... | lld:pubmed |
| pubmed-article:9784102 | pubmed:meshHeading | pubmed-meshheading:9784102-... | lld:pubmed |
| pubmed-article:9784102 | pubmed:meshHeading | pubmed-meshheading:9784102-... | lld:pubmed |
| pubmed-article:9784102 | pubmed:meshHeading | pubmed-meshheading:9784102-... | lld:pubmed |
| pubmed-article:9784102 | pubmed:meshHeading | pubmed-meshheading:9784102-... | lld:pubmed |
| pubmed-article:9784102 | pubmed:meshHeading | pubmed-meshheading:9784102-... | lld:pubmed |
| pubmed-article:9784102 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9784102 | pubmed:articleTitle | Design of new topoisomerase II inhibitors based upon a quinobenzoxazine self-assembly model. | lld:pubmed |
| pubmed-article:9784102 | pubmed:affiliation | Drug Dynamics Institute and Division of Medicinal Chemistry, College of Pharmacy, The University of Texas at Austin, Austin, Texas 78712-1074, USA. | lld:pubmed |
| pubmed-article:9784102 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9784102 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:9784102 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:9784102 | lld:chembl |
